Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial

Alexander M.M. Eggermont, Vanna Chiarion-Sileni, Jean Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A. Ascierto, Jon M. Richards, Céleste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Cyril Konto, Axel Hoos, Veerle de Pril, Ravichandra Karra Gurunath, Gaetan de SchaetzenStefan Suciu, Alessandro Testori

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

1061 Citaten (Scopus)

Sorteer per
Gewicht
Alfabetische volgorde

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial

Vingerafdruk

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science